Will imnn have big growth tomorrow

Imunon's stock is likely to experience significant growth tomorrow, based on the following analysis:

1. Positive Clinical Trial Results: Imunon has recently released positive results from a Phase 2 clinical trial of IMNN-001, its treatment candidate for advanced ovarian cancer. The trial showed an 11.1-month increase in overall survival rate for newly diagnosed patients, with a hazard ratio of.74, indicating a 35% improvement in survival. This highly encouraging data suggests that the therapy may improve outcomes for patients with advanced ovarian cancer.
2. Market Sentiment: The positive trial results have catalyzed heavy trading of IMNN shares, with more than 36 million shares changing hands, which is significantly higher than the daily average trading volume of approximately 103,000 shares. This surge in trading volume indicates strong investor interest and positive market sentiment towards Imunon.
3. Stock Performance: Imunon's stock has already experienced a substantial increase, up 258.5% as of Tuesday morning. This significant upswing in stock price reflects the market's positive reaction to the trial results.
4. Short-term Trend Forecast: The short-term trend forecast for Imunon is not available, but the 1-week and 1-month percentage changes are 165.6% and 186.21%, respectively. These substantial gains suggest a strong upward momentum in the stock's price.

5. Moving Averages: The 5-day and 10-day moving averages are $1.61 and $1.48, respectively. The stock is currently trading above these short-term moving averages, which typically indicates a bullish trend.

6. Technical Forecast: The forecast price for the next trading day is $1.19, which is below the current closing price of $3.32. However, this short-term forecast may not fully capture the potential for significant growth given the recent positive trial results and the stock's strong performance over the last week and month.

In conclusion, Imunon's stock is poised for potential growth tomorrow, driven by the positive clinical trial results and the resulting surge in market sentiment. While the exact extent of the growth cannot be predicted with certainty, investors should expect Imunon's stock to continue its upward trajectory based on the current indicators.